VLA — Valneva SE Share News
0.000.00%
Last trade - 00:00- €440.83m
- €529.53m
- €174.66m
Valneva falls as UK regulator revokes Ixchiq vaccine authorisation
Brief: Valneva Provides Update On Ixchiq® In The United Kingdom
Valneva surges after EU regulator validates Lyme disease vaccine application
Brief: Pfizer And Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated By European Medicines Agency
Valneva falls after H1 revenue, operating profit drop
France's Valneva H1 loss widens on expected drop in revenue
Brief: Valneva H1 Revenue EUR 65.8 Million
Strong base, 'shot at Lyme' - TD Cowen starts Valneva at 'buy'
French and Benelux stocks-Factors to watch
Brief: Gerd Zettlmeissl Appointed As Chair Of The Board Of Directors
Brief: Valneva SE - Files For Offer And Resale From Time To Time By Selling Securityholders Of Up 31.6 Million Ordinary Shares
Valneva Q1 revenue falls, net loss widens; FY guidance cut on weaker travel vaccine demand
Brief: Valneva Q1 Revenue EUR 30.9 Million
Brief: Valneva: Successful Completion Of EUR 84 Mln Reserved Offering
GS turns bearish on Valneva after 'multiple disappointments', slashes PT
Analysis: COVID shots, newer vaccines in limbo after US court halts Kennedy’s advisory panel
Pfizer-Valneva Lyme vaccine shows more than 70% efficacy but misses key goal (updated)
Valneva slumps after Lyme disease vaccine's late-stage trial misses target
Brief: Pfizer Says LB6V Vaccine Candidate Was Well Tolerated With No Safety Concerns Identified At Time Of Analysis